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ABSTRACT
Localized prostate cancer (PCa) is a manageable disease but for most men 
with metastatic disease, it is often fatal. A western diet has been linked with PCa 
progression and hyperglycaemia has been associated with the risk of lethal and fatal 
prostate cancer.
Using PCa cell lines, we examined the impact of IGF-I and glucose on markers 
of epithelial-to-mesenchymal transition (EMT), migration and invasion. We examined 
the underlying mechanisms using cell lines and tumour tissue samples.
IGF-I had differential effects on the process of EMT: inhibiting in normal and 
promoting in cancer cells, whereas hyperglycamia alone had a stimulatory effect 
in both. These effects were independent of IGF and in both cases, hyperglycaemia 
induced an increase IGFBP-2(tumour promoter) and FOXA1. A positive correlation 
existed between levels of IGFBP-2 and FOXA1 in benign and cancerous prostate tissue 
samples and in vitro and in vivo data indicated that FOXA1 strongly interacted with the 
IGFBP-2 gene in normal prostate epithelial cells that was associated with a negative 
regulation of IGFBP-2, whereas in cancer cells the level of FOXA1 associating with 
the IGFBP-2 gene was minimal, suggesting loss of this negative regulation.
IGF-I and hyperglycaemia-induced FOXA1/IGFBP-2 play important roles in EMT.
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INTRODUCTION
Despite advances in the detection and management 
of prostate cancer, tumour recurrence is common and often 
progresses to hormone refractory metastatic disease that 
accounts for most prostate cancer-associated mortalities. 
Epithelial-to-mesenchymal transition (EMT) appears to 
play a crucial role in the progression of metastatic prostate 
cancer [1]. During EMT, epithelial cancer cells lose their 
cell-cell adhesion and acquire the motile and invasive 
characteristics of mesenchymal cells that are essential for 
dissemination and distant metastasis [2]. Loss of epithelial 
markers such as E-cadherin and β-catenin together with 
the acquisition of mesenchymal markers such as vimentin 
and fibronectin are the hallmarks of EMT activation.
The causes of the development of clinically 
aggressive prostate cancer are not entirely understood, 
but it was proposed that apart from genetic mutations, 
adoption of a western lifestyle contributes to the increase 
in prevalence and progression to clinical disease. Studies 
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have shown an association between metabolic syndrome 
and an increased risk of prostate cancer progression to 
advanced disease and prostate cancer-specific mortality 
[3, 4]. Epidemiologic evidence suggest that suffering from 
diabetes is associated with a higher risk of developing, 
and mortality from, many types of cancers including 
liver, pancreatic, colon, endometrial, kidney and breast 
[5]. A recent meta-analysis revealed that prostate 
cancer patients with pre-existing diabetes have a worse 
prognosis and higher mortality [6]. The underlying 
mechanisms linking diabetes and cancer development 
are yet to be fully determined; but it has been suggested 
that hyperglycaemia, a hallmark of diabetes may promote 
tumour progression [7].
Growing evidence has shown that dysregulation 
of the insulin-like growth factor (IGF) signalling 
pathway contributes to cancer progression and 
malignant transformation [8]. Epidemiology studies have 
consistently shown an association between circulating 
plasma IGF-I with the increased risk and progression 
of prostate cancer [9–12, 13]. Immunohistochemistry 
analysis of serial resected prostate cancer specimens 
found an increase in the IGF receptor (IGF-IR) 
in androgen-independent metastatic disease [14]. 
IGFBP-2, the second most abundant IGF-binding 
protein (IGFBP) in serum after IGFBP-3, plays a crucial 
role in modulating IGF-activity. IGFBP-2 binding to 
IGFs regulates the bioavailability of the ligands to the 
receptors and their half-life in the circulation [15]. Apart 
from its IGF-dependent actions, IGFBP-2 also exerts 
effects on cell growth and metabolism independent of 
IGF [16]. We have reported that IGFBP-2 can promote 
prostate tumour progression by acting as a growth 
promoter, a survival factor against docetaxel-induced 
cell death [17] and that hyperglycaemia-induced up-
regulation of IGFBP-2 conferred chemo-resistance in 
prostate cancer cells [18]. FOXA1 has been identified 
as a “pioneer factor” that binds to the chromatin-
packaged DNA and opens the chromatin for binding of 
additional transcription factors including the androgen 
receptor (AR) [19]. Reports on the role of FOXA1 in 
cancer have been controversial. FOXA1 has been 
shown to have positive and negative effects on cancer 
progression [20–24] and is also an important mediator 
of IGF-I mediated biological responses. In response to 
IGF-I activation AKT phosphorylates FOXA1 promoting 
its association with 14-3-3 proteins resulting in its 
exclusion from the nucleus, thus preventing its actions 
on DNA. IGF-I regulated genes are enriched with 
FOXA1 binding sites and FOXA1 suppression inhibits 
the ability of IGF-I to regulate gene expression involved 
in cell proliferation and survival via both MAPK and 
AKT signaling pathways [25]. In this study, we aimed to 
assess the effects of hyperglycaemia and IGF-I on EMT 
in normal and malignant prostate epithelial cells. We also 
investigated the potential mechanism that mediated the 
effect of hyperglycaemia on EMT by assessing the role 
of IGFBP-2 and FOXA1.
RESULTS
The effect of IGF-I on EMT markers in prostate 
epithelial cells in altered glucose conditions
We first assessed the differential abundance of 
epithelial and mesenchymal proteins in a panel of prostate 
cancer cell lines and in a non-tumourigenic PNT2 
prostate epithelial cell line (Supplementary Figure 1A). In 
agreement with a study by Murali in 2012 [26], E-cadherin 
was highly abundant in LNCaP cells, with lower levels 
in the more aggressive VCaP and DU145 cells. The 
most mesenchymal, PC3 cells had no E-cadherin but 
did possess high levels of the mesenchymal marker 
N-cadherin. β-catenin and vimentin were found in all the 
cell lines, with lower and higher abundance respectively 
in the more aggressive VCaP, DU145 and PC3 cells. It is 
also interesting to note, that despite the non-tumourigenic 
characteristic of PNT2, these cells expressed very low 
levels of E-cadherin and high levels of N-cadherin 
suggesting some intrinsic phenotypic plasticity for EMT. 
From our panel of cell lines, we chose to use PNT2 cells 
as a representative of normal prostate epithelial cells 
and DU145 cells which represent an androgen receptor 
negative prostate cancer cell line to compare if there were 
any differences in response to hyperglycaemia and IGF-I 
with these two cell lines.
With PNT2 cells, grown in 5 mM glucose, there 
was a significant (p < 0.01) increase in E-cadherin 
abundance and a reduction (p < 0.05) in fibronectin and 
vimentin respectively following treatment with IGF-I for 
48 hours compared to the untreated controls. No changes 
in β-catenin levels were observed (Figure 1A and 1B). 
These findings suggest that IGF-I has an inhibitory effect 
on EMT and induces mesenchymal-to-epithelial transition 
(MET) in PNT2 cells.
In contrast, opposite effects were observed with 
DU145 in 5 mM glucose. IGF-I induced EMT in DU145 
cells as shown by a significant reduction of E-cadherin 
and β-catenin abundance respectively (p < 0.01 and p < 
0.05). The reduction in these epithelial markers was also 
accompanied by a significant (p < 0.05) increase in the 
mesenchymal marker vimentin but no changes in the level 
of fibronectin were observed (Figure 1A and 1C).
With PNT2 cells grown in 25 mM glucose, high 
glucose alone altered some of the EMT markers: it 
reduced E-cadherin (p < 0.05), increased fibronectin and 
vimentin (p = 0.01 and p < 0.05 respectively) and had no 
effect on β-catenin. Despite high glucose alone promoting 
EMT, IGF-I still decreased both fibronectin and vimentin 
and had no effect on β-catenin or E-cadherin (Figure 1A 
and 1C)
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With DU145 cells, 25 mM glucose alone promoted 
EMT with a significant increase in the mesenchymal 
markers fibronectin and vimentin (p < 0.01 and p = 
0.01) compared to untreated control in normal glucose 
conditions. E-cadherin levels were also decreased (p < 
0.05) but there were no significant change in β-catenin 
levels. Treatment with IGF-I in high glucose conditions 
resulted in a further decrease in E-cadherin levels (p < 
0.05) but there were no significant changes observed in 
fibronectin and vimentin when compared to the untreated 
high glucose controls (Figure 1A and 1C).
The effect of hyperglycaemia and IGF-I on 
β-catenin phosphorylation and subcellular 
localisation
With PNT2 cells, β-catenin phosphorylation was 
increased by IGF-I in both normal and high glucose 
conditions and this was not affected by levels of glucose 
(Figure 1D and 1E). With DU145 cells, high glucose alone 
was able to significantly induce β-catenin phosphorylation 
(p < 0.01) when compared to untreated controls in normal 
glucose conditions. Treatment with IGF-I promoted 
β-catenin phosphorylation in normal levels of glucose but 
in high glucose conditions was unable to further increase 
the phosphorylation when compared to high glucose 
alone, although the level was still high when compared to 
untreated control in normal glucose conditions (Figure 1F, 
1G). High glucose alone promoted nuclear localisation of 
β-catenin in DU145 cells (Figure 1H and 1I). Dosing with 
IGF-I in normal glucose conditions increased translocation 
of β-catenin to the nucleus whereas in high glucose 
conditions the addition of IGF-I had no further effect.
The effect of IGF on cell proliferation and 
migration in prostate epithelial cells in altered 
glucose condition
With PNT2 cells, addition of IGF-I in normal 
glucose conditions induced an increase in cell proliferation 
(p < 0.05) similarly to when the cells were grown in high 
glucose conditions alone (p < 0.05). However, addition of 
IGF-I in high glucose conditions was not able to induce a 
further increase in cell proliferation (Figure 2A).
With DU145 cells, addition of IGF-I in normal 
glucose conditions induced an increase in cell proliferation 
(p < 0,05) similarly to when the cells were grown in high 
glucose conditions alone (p < 0.05). In contrast to PNT2 
cells, with DU145 cells, addition of IGF-I in high glucose 
conditions further increased cell proliferation significantly 
when compared to high glucose alone (p < 0.05)(Figure 2A).
Even though similar proliferative effects of IGF-I 
were observed in the PNT2 and DU145 cells, its effect on 
the migratory ability was different. Figure 2B and 2C show 
that with 5 mM glucose, IGF-I decreased migration of 
normal PNT2 cells but promoted migration of the DU145 
prostate cancer cells: this reflected the changes observed 
in the EMT markers upon IGF exposure. However, 
exposure of PNT2 cells to high glucose alone markedly 
increased cell migration (p < 0.05) but was still inhibited 
in the presence of IGF-I (p < 0.05). Similar to PNT2 cells, 
exposure to high glucose alone increased DU145 cell 
migration (p < 0.05) but the addition of IGF-I under high 
glucose conditions could not enhance migration further.
Effect of IGF-I on AKT and MAPK signaling 
in prostate epithelial cells in altered glucose 
conditions
With PNT2 cells, addition of IGF-I in normal and 
high glucose conditions increased phosphorylation of 
the IGF-IR, AKT and MAPK time dependently. With 
DU145 cells, the IGF-IR and its downstream target AKT 
were also activated upon treatment with IGF-I, whereas 
IGF-I decreased the phosphorylation of MAPK. These 
results are consistent with the action of IGF-I in regulating 
EMT in both cell lines, being dependent on the IGF-IR in 
normal and high glucose conditions. However, exposing 
both PNT2 and DU145 to high glucose conditions alone 
[25 mM compared with 5 mM] did not activate the IGF 
pathway despite the promotion of EMT observed in these 
cells suggesting that the induction of EMT by high glucose 
was not regulated through activation of the IGF pathway 
(Figure 3A). To further verify that the effect of high 
glucose was independent of IGF-IR signalling in PNT2 
and DU145 cells, the activation of the IGF-IR was blocked 
using an IGF-IR inhibitor, AG1024 and the changes in cell 
proliferation were examined. With PNT2 cells, inhibition 
of the IGF-IR was found to significantly reduce cell 
proliferation in normal glucose conditions by approximately 
25% (p < 0.05). However, inhibition of the IGF-IR in high 
glucose conditions was not able to inhibit high glucose-
induced proliferation of PNT2 cells. With DU145 cells, 
high glucose alone increased cell proliferation. Similarly, 
inhibition of the IGF-IR in normal glucose conditions 
inhibited proliferation of DU145 cells, as had been 
observed with PNT2 cells. In high glucose conditions, IGF-
IR inhibition was also found to partially reduce DU145 cell 
proliferation (p < 0.05) but was still higher when compared 
to IGF-IR inhibition in normal glucose condition (p < 0.05)
(Figure 3B). Taken together, these findings show that the 
effects of high glucose in inducing PNT2 and DU145 cell 
proliferation were independent of the type I IGF receptor; 
suggesting that an alternative pathway might be involved 
in mediating the effects of high glucose in promoting 
proliferation in prostate cells.
Association between IGFBP-2 and FOXA1 in 
prostate epithelial cells
We analysed the levels of FOXA1 and IGFBP-2 in 
a panel of prostate cancer and normal prostate epithelial 
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cells (Supplementary Figure 2). Although there was great 
heterogeneity among the cell lines, with most of the cell 
lines, there was a good correlation between basal FOXA1 
and IGFBP-2 abundance. FOXA1 was found to be highly 
expressed in VCaP, LNCaP and PC3 cells. A very low 
level of FOXA1 was found in non-malignant PNT2 cells 
and malignant DU145 cells. IGFBP-2 expression was also 
found to be high in VCaP and LNCaP cells but very low 
in DU145 cells. With PC3 cells, the expression of FOXA1 
and IGFBP-2 did not follow the same pattern observed 
in other cell lines. High FOXA1 but low IGFBP-2 levels 
were found in PC3 cells. Although there seemed to be no 
abundance of IGFBP-2 in PNT2 and PC3 cells this was 
likely due to the other bands corresponding to VCaP and 
LNCaP being excessively strong resulting in the imager 
not detecting the fainter bands.
Figure 4A and 4B show that hyperglycaemia induced 
a large increase in the level of FOXA1 in both PNT2 and 
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Figure 1: The effect of IGF-I on EMT markers in prostate epithelial cells in altered glucose condition. (A) Western 
blot image shows the effect of IGF-I and high glucose on mesenchymal markers in PNT2 and DU145 cells. Cells were dosed with IGF-I 
100 ng/ml for 48 hours in normal (5 mM) and high (25 mM) glucose serum free media. Equal amounts of extracted proteins were separated 
by SDS-PAGE, blotted to a nitrocellulose membrane. We then cut the membrane into strips, horizontally according to molecular weight 
markers, to probe the membrane with different antibodies for different sized proteins of interest: E-cadherin, β-catenin, fibronectin, vimentin 
and GAPDH. GAPDH was used as a loading control. The framed boxes sometimes include areas larger than the strips and therefore appear 
as no background. Optical densities of protein blots for  (B) PNT2 and (C) DU145 were quantitated using image J and normalised to 
GAPDH. Western blots showing regulation of p-β-catenin in (D) PNT2 and (E) DU145 cells when treated with 100 ng/ml IGF-I in normal 
(5 mM) and high (25 mM) glucose serum free media. Optical densities of protein blots for (F) PNT2 and (G) DU145 were quantitated using 
image J and normalised to GAPDH. Ratio of normalised total β-catenin: p- β-catenin were measured and used as an indicator of β-catenin 
activity. The data expressed as fold changes relative to control represent mean ± SE of triplicate experiments. (H) Western blot showing 
cytosolic and nuclear fractions of protein separated form whole cells lysate (total protein) from DU145 cells treated or untreated with 100 ng/
ml IGF-I for 48 hours in normal (5 mM) and high (25 mM) glucose serum free media. Lamin A/C and tubulin act as nuclear and cytoplasmic 
loading controls respectively. (I) Optical densities of protein blots were quantitated using image J and normalised to tubulin/lamin. Results 
shown are representative of three independent experiments. Data are represented as mean ± SEM.
Oncotarget2548www.oncotarget.com
Figure 2: The effect of IGF on cell proliferation and migration in prostate epithelial cells in altered glucose condition. 
(A) PNT2 and DU145 cells were treated with 100 ng/ml IGF-I for 48 hours in normal (5 mM) and high (25 mM) glucose condition and 
changes in cell proliferation were assessed by direct count of viable cells in a haemocytometer. The plotted values represent means of 
percentage change relative to control. (B) Cell migration was measured using the transwell migration assay. PNT2 and DU145 cells were 
plated in the upper chamber of the inserts and treated with IGF-I (100 ng/ml) under normal (5 mM) and high (25 mM) glucose conditions. 
After 17 h, cells in the insert (non-migrated cells) were eliminated by scraping and migrated cells were stained with 4’,6-diamidino-2-
phenylindole (DAPI) and counted under flourescence microscope. (C) Graph shows the percentage of cells migrated relative to control 
(non treated in normal glucose condition). All results shown are representative of three independent experiments. Data are represented as 
mean±SEM. Significant value observed as p < 0.05.
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DU145 cell lines (this was also observed with LNCaP 
cells, Supplementary Figure 1B). Having shown previously 
that IGFBP-2 is also regulated by hyperglycaemia we 
investigated if these two molecules might regulate EMT in 
prostate cells exposed to high levels of glucose. First, we 
investigated if there was an association between IGFBP-2 
and FOXA1. We examined the effect of FOXA1 silencing 
on IGFBP-2 abundance in PNT2 and DU145 cells. With 
PNT2 cells, FOXA1 silencing induced a significant 
increase in IGFBP-2 (p < 0.01). However, with DU145 
cells, a different effect was observed with a a significant 
reduction (p < 0.05) in the level of IGFBP-2 when FOXA1 
was silenced when compared to a non-silencing control 
(Figure 4C and 4D; this was also observed with LNCaP 
cells, Supplementary Figure 1C). These data suggest that 
FOXA1 is a negative regulator of IGFBP-2 in normal but 
not in the cancer cells. Successful knock-down of FOXA1 
is shown by western blot image and graphs of optical 
Figure 3: High glucose-induced EMT in prostate cells is independent of IGFI-R. (A) Western blot image shows the effect of 
IGF-I on the phosphorylation of IGF-IR, Akt and MAPK in PNT2 and DU145 cells. Cells were dosed with IGF-I 100 ng/ml for 10, 20 and 
30 minutes in normal (5 mM) and high (25 mM) glucose serum free media (SFM). (B) Graph shows relative changes in cells proliferation 
in PNT2 and DU145 cells after IGFI-R receptor inhibition using tyrosine kinase inhibitor (AG1024) in different glucose conditions. Results 
shown are representative of at least three independent experiments. Data are represented as mean±SEM.
Oncotarget2550www.oncotarget.com
density measurements for FOXA1 in all cell lines. Having 
shown that FOXA1 regulated IGFBP-2 levels, we wanted 
to know whether modulating IGFBP-2 expression could in 
turn affect abundance of FOXA1. With PNT2 and DU145 
cells, IGFBP-2 depletion resulted in increased FOXA1 
abundance (p < 0.05 and p < 0.01 respectively) (Figure 4C 
and 4D). Using CHiP analysis, we then assessed if there 
was an interaction between FOXA1 and the IGFBP-2 
gene. Compared with PNT2 cells, the association was 
decreased by 82% (p < 0.01) in DU145 cells and by 76% 
(p = 0.05) in LNCaP cells (Figure 4E), indicating a strong 
interaction between FOXA1 and the IGFBP-2 gene in 
normal prostate cells and a markedly reduced interaction 
between the two in cancer cells
A role for FOXA1/IGFBP-2 in high glucose-
induced EMT
Silencing of FOXA1 in PNT2 cells promoted a 
more epithelial-like phenotype as demonstrated by a 
significant increase in the epithelial marker E-cadherin 
(p = 0.01) and a significant reduction in the mesenchymal 
markers N-cadherin (p < 0.05) and vimentin (p < 0.05). 
An unexpected increase in fibronectin was also observed 
when FOXA1 was silenced. Similarly, IGFBP-2 silencing 
in PNT2 resulted in a significant increase in E-cadherin 
levels (p = 0.01) but no significant changes were observed 
in mesenchymal markers (Figure 5A).
With DU145 cells, FOXA1 and IGFBP-2 silencing 
were both found to repress EMT as demonstrated by an 
up-regulation of E-cadherin by (p = 0.01 and p = 0.01) 
respectively when compared to a non-silencing control. 
Depletion of FOXA1 and IGFBP-2 levels were also found 
to reduce vimentin (p < 0.01) and fibronectin (p < 0.01 and 
p < 0.01) respectively (Figure 5B).
With PNT2 cells, FOXA1 silencing did not alter 
the migratory ability but induced a slight reduction in cell 
invasion (p < 0.05). Unexpectedly, IGFBP-2 silencing 
induced cell migration and invasion by approximately 
60% (p < 0.05) and 15% (p < 0.05) respectively (Figure 
5C). Interestingly, with DU145 cells, FOXA1 silencing 
induced a reduction in cell migration and invasion by 
25% (p < 0.01) and 40% (p < 0.01) respectively. Similar 
findings were observed when IGFBP-2 was silenced; 
a reduction in the migratory and invasive potential of 
DU145 by 50% (p < 0.05) and 40% (p < 0.01) respectively 
were found (Figure 5D).
Positive association between FOXA1 and 
IGFBP-2 level in prostate cancer tissue
As shown in Figure 6, IGFBP-2 was predominantly 
confined to the cytoplasm with weak stromal staining. 
Interestingly, nuclear localisation of IGFBP-2 was also 
observed in both adjacent benign and prostate cancer 
cases (Figure 6A). IGFBP-2 was observed in both adjacent 
benign tissue as well as in the cancer region and showed 
no significant difference between them in the smaller 
cohort (p = 0.274), however in the larger PrEvENT cohort, 
IGFBP-2 expression was significantly increased in cancer 
compared to benign tissue (p = 0.001). Correlation analysis 
between IGFBP-2 and clinicopathological parameters of 
prostate cancer showed that IGFBP-2 was not significantly 
associated with age (p = 0.834), pre-operative PSA level 
(p = 0.051), Gleason score (p = 0.192), pathologic stage 
(p = 0.813) or lymph node involvement (p = 0.850) 
in the Southmead cohort (Table 1). Similarly, in the 
PrEvENT cohort there was no significant correlation 
between IGFBP-2 and age (p = 0.432), pre-operative PSA 
(p = 0.354) or pathologic stage (p = 0.922), however 
there was a significant association with Gleason Score 
(p = 0.022). We were not able to statistically assess the 
association with lymph node invasion in this cohort due to 
this information being unavailable for many of the patients.
FOXA1 was found to be predominantly confined 
to the nucleus of epithelial prostate cancer cells as well 
as in adjacent benign tissue (Figure 6A). There was no 
significant difference observed in the FOXA1 staining 
between these tissues in either cohort (p = 0.665, 
p = 0.151). In both cohorts, the expression of FOXA1 
was also not significantly associated with age (p = 0.582, 
p = 0.711), pre-operative PSA levels (p = 0.288, 
p = 0.209), Gleason score (p = 0.645, p = 0.270), 
pathologic stage (p = 0.544, p = 0.279) or lymph node 
involvement (p = 0.787, p = 0.114)(Table 1). Interestingly, 
in the smaller tissue cohort we found a positive correlation 
between FOXA1 and IGFBP-2 levels (r = 0.319, p = 0.029) 
in prostate cancer tissue. Although, in benign tissue, there 
was a trend for positive correlation between these proteins, 
this was not statistically significant (r = 0.259, p = 0.079) 
(Figure 6B). In the larger PrEvENT cohort, the association 
was significant in both benign tissue (r = 0.249, p = 0.014) 
and cancer tissue (r = 0.219, p = 0.033).
This finding supports the evidence from the in vitro 
study that showed an association between FOXA1 and 
IGFBP-2 in prostate epithelial cells.
DISCUSSION
The bioactivity of IGF-I is intricately integrated 
with nutritional status and energy balance; and 
alterations in metabolism associated with adoption of a 
western lifestyle have been postulated to contribute to 
the increased risk of developing prostate cancer [27]. 
Increased expression of IGF-I has been associated with 
poor prognosis and more aggressive cancers that exhibit 
increased metabolism and increased glucose uptake. 
The activation of the EMT program contributes to the 
progression of metastatic prostate cancer, which is 
the principle cause of death in most of prostate cancer 
patients. In this study we investigated the role of IGF-I 
in promoting prostate cancer progression through 
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Figure 4: Association between IGFBP-2 and FOXA1. (A) Western blot image showing the effect of different glucose concentration 
on the level of FOXA1 in PNT2 and DU145 cells. (B) Optical densities of protein blots were quantitated using image J and normalised 
to GAPDH. (C) Western blot image showing the effect of stable knockdown of FOXA1 and IGFBP-2 on IGFBP-2 and FOXA1 levels in 
PNT2 and DU145 cells in high glucose conditions. (D) Optical densities of protein blots were quantitated using image J and normalised to 
GAPDH. The data expressed as relative changes relative to control (non-silencing). All results shown are representative of three independent 
experiments. Data are represented as mean ± SEM. Significant value observed as p < 0.05 (E) Results from real time PCR showing relative 
fold change levels of FOXA1 protein associating with the IGFBP-2 gene associated with normal epithelial prostate cells PNT2 and two 
prostate cancer cell lines DU145 and LNCaP, in high glucose conditions, after performing a chromatin immunoprecipitation (ChIP) assay. 
Graph represents the mean of relative fold change from three separate experiments (n = 3).
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Figure 5: A role for FOXA1/IGFBP-2 in high glucose-induced EMT Western blots images showing the effect of stable knock down of 
FOXA1 and IGFBP-2 on EMT in (A) PNT2 and (B) DU145 cells. Graphs represent the western blots images and show the optical densities 
of the blots quantitated using image J and normalised to GAPDH/Tubulin. The data are expressed as fold changes relative to control 
(non-silencing). (C), (D) The effect of stable knock down of FOXA1 and IGFBP-2 on migration and invasion of PNT2 and DU145 cell 
using transwell migration/invasion assay. FOXA1 and IGFBP-2 were knocked down in PNT2 and DU145 cells for 72 hours, trypsinised, 
counted and plated in the upper chamber of the inserts. After 17 h, cells in the insert (non-migrated cells) were eliminated by scraping and 
migrated cells were stained with 4’,6-diamidino-2-phenylindole (DAPI) and counted under flourescence microscope. Graphs below each 
image show the percentage of cells migrated and invaded relative to control (non silencing). All results shown are representative of three 
independent experiments. Data are represented as mean±SEM. Significant value observed as p < 0.05
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activation of the EMT program. With normal PNT2 
cells, under euglycaemic conditions, EMT was inhibited 
by IGF-I, whereas opposite effects were observed in the 
cancer cells, which suggest that with normal epithelial 
prostate cells, IGF-I prevented a malignant phenotype by 
maintaining the normal characteristics of differentiated 
cells whereas in cancer cells, IGF-I promoted a more 
mesenchymal phenotype that could potentially promote a 
more aggressive phenotype.
The ability of IGF-I to induce EMT in prostate 
cancer cells was also consistent with studies conducted 
in brain [28] and breast [29] cancer cell lines. Similar 
observations were made by Graham et al (2015) where 
IGF-I induced EMT in ARCaP prostate cancer cells 
through up-regulation of Zinc finger E-box-binding 
homeobox (ZEB1), a transcription factor that regulated 
EMT activation [30].
IGF-I induced cell proliferation in both cancer 
and non-cancerous cells confirming its mitogenic role in 
regulating cell growth and differentiation in wide variety 
of cells as reported in the literature [31, 32]. Even though 
similar proliferative effects of IGF-I were observed in 
cancer and non-cancerous cells, its effect on the migratory 
ability was different. IGF-I decreased migration of normal 
PNT2 cells but promoted migration of the DU145 prostate 
cancer cells: this reflected the changes observed in the 
EMT markers upon IGF exposure. Increases in E-cadherin 
by IGF-I that was observed with PNT2 cells, tightens the 
cell-cell junctions thus limiting the ability of cells to move 
and migrate. On the other hand, with DU145 cells, IGF-I 
increased the cells’ potential for metastasis as evidenced 
by increases in cell migration.
Epidemiology studies have shown a positive 
association between metabolic syndrome such as obesity and 
Figure 6: (A) IGFBP-2 and FOXA1 expression in prostate cancer tissue. Tissue demonstrating negative staining (0 score), weak 
staining (1 score), moderate staining (3 score), strong staining (3 score) (×20 magnification) and positive IGFBP-2 nuclear expression in 
prostate epithelial cells (see →) (×40 magnification). (B) Association between FOXA1 and IGFBP-2 levels in prostate cancer tissue. (a) 
Hematoxylin and Eosin staining (b) strong IGFBP-2 and (c) FOXA1 staining in the same prostate cancer tissue (×20 magnification). (d) 
bar chart showing the significant increase in IGFBP-2 expression in cancer compared to benign tissue in the PrEvENT cohort and scatter 
plots showing the significant positive association between FOXA1 and IGFBP-2 proteins level in prostate cancer tissue in the Southmead 
(e) and PrEvENT (f) cohorts.
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diabetes with cancer development and mortality. Increases 
in IGF-I levels appear to be one of the factors linking these 
different diseases [33]. Hyperglycaemia, a hallmark of 
diabetes, has been shown to promote cancer progression 
[7]. We have also shown previously that hyperglycaemia 
induced chemoresistance in prostate cancer cells [18]. In 
this study, we revealed for the first time that exposure to 
high concentrations of glucose (25 mM) alone induced 
EMT in both cancer and non-cancerous prostate epithelial 
cells compared to normal glucose (5 mM) conditions. The 
transition from epithelial to mesenchymal characteristics 
in these cell lines was also correlated with increases in 
proliferation and migratory potential in both cell lines. 
More interestingly, with PNT2 cells, despite the ability of 
hyperglycaemia alone to induce EMT, the effects were still 
reversed by addition of IGF-I: IGF-I was able to promote an 
epithelial phenotype in PNT2 cells in both normal and high 
levels of glucose. However, with DU145 cells, addition of 
IGF-I in high glucose conditions was not able to augment the 
effect of high glucose alone on EMT. These data suggested 
that different concentrations of glucose do not influence the 
action of IGF-I and that glucose alone can independently 
promote tumour aggressiveness and metastasis.
The involvement of hyperglycaemia in prostate 
cancer cell EMT, progression and metastasis may 
underpin why prostate cancer patients that present with 
hyperglycaemia have a worse prognosis. High intake of 
total energy has been associated with increased risk of 
Table 1: Clinical and pathological features of the Southmead and PrEvENT prostate tissue cohorts and their association 
with FOXA1 and IGFBP-2 expression
Variables
Southmead Cohort PrEvENT Cohort
Median (range) 
or n (%) P for c2
Median (range) 
or n (%) P for c2
FOXA1 IGFBP-2 FOXA1 IGFBP-2
N 47 95
Age at Surgery 64 (46-76) 0.582 0.834 65 (45-74) 0.711 0.432
≤64 24 (51.1%) 47 (49.5%)
>64 23 (48.9%) 48 (50.5%)
Pre-operative PSA  
(ng/ml) 11.7 (1.2-74) 0.288 0.051 8.6 (2.2-70) 0.209 0.354
<10 21 (44.7%) 55 (57.9%)
10-20 15 (31.9%) 28 (29.5%)
>20 11 (23.4%) 6 (6.3%)
Unknown 0 (0%) 6 (6.3%)
Gleason Grade 0.645 0.192 0.27 0.022
<7 14 (29.7%) 11 (11.6%)
7 21 (44.7%) 76 (80%)
>7 12 (25.5%) 6 (6.3%)
Unknown 0 (0%) 2 (2.1%)
Pathologic Stage 0.544 0.813 0.279 0.922
pT2 14 (29.7%) 28 (29.5%)
pT3a 21 (44.7%) 44 (46.3%)
pT3b 12 (25.5%) 12 (12.6%)
pT4 0 (0%) 1 (1.1%)
Unknown 0 (0%) 10 (10.5%)
Lymph node 
invasion 0.787 0.850





P values indicate any changes in expression levels with clinicopathological features across the range of each cohort.
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fatal prostate cancer [34]. Dietary restriction and lifestyle 
changes are suggested as an intervention for suppresion 
of cancer growth. A study of calorie restriction performed 
in mice showed a reduction in circulating IGF-I and 
insulin levels and deactivation of the PI3K/AKT pathway 
which resulted in prostate tumour growth inhibition [35]. 
In addition, calorie restriction combined with IGF-1R 
blockade resulted in growth inhibition in prostate cancer 
xenografts [36]. Taken together, this evidence suggests that 
limiting energy consumption may reduce the risk of prostate 
cancer progression by improving the metabolic profile.
β-catenin plays an important role in both 
maintaining epithelial integrity and as a co-activator 
of Wnt-mediated gene transcription. The activation of 
Wnt/ β-Catenin signalling has been shown to promote 
EMT in prostate cancer. This study revealed that IGF-I 
promoted destabilization of β-catenin by inducing its 
phosphorylation at Ser33/37/T41 in both PNT2 and 
DU145 cells and that this effect was not affected by 
levels of glucose. It is also interesting to note that despite 
this observation (destabilization of β-catenin), IGF-I 
also induced β-catenin nuclear translocation, which 
is indicative of Wnt/β-catenin transcriptional activity. 
Likewise, increased hyperglycaemic conditions alone 
had the same effect on β-catenin phosphorylation and 
nuclear translocation in DU145 in contrast to the PNT2 
cells although in both cell lines hyperglycaemia yielded a 
similar effect on EMT.
IGF-I exerts its biological effects through binding 
to its receptor, predominantly the IGF-IR, activating 
downstream signalling cascades. With PNT2 cells, both 
IGF-IR/PI3K/AKT and IGF-IR/RAS/MAPK pathways 
were found to be equally activated by IGF-I whereas 
with DU145 cells, IGF-IR/PI3K/AKT appeared to be 
the dominant signalling pathway in mediating IGF-
I-induced EMT in DU145 cells. In contrast to IGF-I, 
hyperglycaemia did not induce activation of the IGF-IR 
or components of the IGF-IR signalling pathway (p-AKT 
or p-MAPK) in either cell model although all the features 
of EMT were enhanced by hyperglycaemia in a similar 
way to IGF-I in euglycaemic conditions. This suggests that 
hyperglycaemia-induced EMT in PNT2 and DU145 cells 
was independent of IGF signalling, that was confirmed 
using AG1024 a tyrosine kinase inhibitor to block IGF-
IR activation. In euglycaemic conditions, blocking 
the IGF-IR reduced cell growth as expected, however 
in hyperglycaemic conditions, the hyperglycaemia-
induced effect of increasing cell proliferation was 
unaffected. This shows that a different mechanism in 
which hyperglycaemia activates the EMT program was 
involved: one of which could be through the regulation by 
IGFBP-2. There is accumulating evidence that IGFBP-2 
may have an important role in prostate cancer progression 
[37]. We have shown previously that IGFBP-2 promotes 
prostate cancer growth in both an IGF-I-dependent and 
independent manner [17] and that hyperglycaemia induced 
up-regulation of IGFBP-2 in prostate cancer cells which 
resulted in resistance to chemotherapy [18].
Apart from IGFBP-2, an increase in the level of 
FOXA1 by hyperglycaemia in prostate cell lines was 
also observed in this study. In light of these findings, 
we investigated if there was interplay between IGFBP-2 
and FOXA1. Our in vivo study indicated that a positive 
correlation existed between levels of IGFBP-2 and FOXA1 
in benign and cancerous prostate tissue samples. With the 
CHiP analysis using cell lines, we found that FOXA1 
strongly interacted with the IGFBP-2 gene in normal 
prostate epithelial. The siRNA data showed that silencing 
FOXA1 in normal prostate cells resulted in a large increase 
in IGFBP-2. Collectively, these data may suggest that in 
normal prostate epithelial cells, FOXA1 binds to the 
IGFBP-2 gene to negatively regulate IGFBP-2 levels.
With the cancer cells, CHiP analysis indicated that 
the level of FOXA1 associating with the IGFBP2 gene 
was minimal in comparison to the normal cells. siRNA 
also indicated that the relationship between FOXA1 
and IGFBP-2 in cancer cells was different, as although 
silencing FOXA1 reduced levels of IGFBP-2, the ratio of 
FOXA1 to IGFBP-2 appeared to remain the same.
It is well established that IGFBP-2 is upregulated 
in many cancers including the prostate and this was 
observed in our own tissue cohort. Our data may suggest 
that FOXA1 keeps IGFBP-2 in check in normal cells, but 
this negative regulation is lost in the cancer cells.
Next, we investigated the ability of FOXA1 and 
IGFBP-2 to regulate EMT in prostate epithelial cells: 
FOXA1 silencing in PNT2 and DU145 cells resulted 
in a more epithelial-like phenotype manifested by an 
increase in the epithelial marker, E-cadherin, and a 
reduction in mesenchymal markers such as vimentin 
and fibronectin. Cell migration and invasion were also 
inhibited following FOXA1 silencing. This would be 
consistent with a previous report that revealed higher 
expression of FOXA1 in prostate cancer than in normal 
prostate tissue that was associated with advanced stages 
of cancer [24]. Moreover, overexpression of FOXA1 was 
also found in metastatic and castration-resistance prostate 
cancer that correlated with higher pT stage and Gleason 
score [38]. FOXA1 silencing in prostate cells was found 
to inhibit cell growth and induced G0/G1 arrest [24] as 
well as induce a reduction in cell migration [38]. However, 
despite all the evidence on the oncogenic role of FOXA1 
in prostate cancer as discussed above, there are also 
reports that reveal its role as a suppressor of EMT. Jin 
et al showed that high expression of FOXA1 suppressed 
EMT, migration and invasion in prostate cancer by directly 
inhibiting SLUG gene expression [21]. Similar findings 
were also reported in pancreatic ductal adenocarcinoma 
[20]. Most recently, a study by Huang et al revealed that 
TRPS1-induced FOXA1 transcriptional activity inhibited 
EMT and metastasis in breast cancer cells [39]. Similarly, 
to FOXA1, IGFBP-2 silencing in DU145 resulted in total 
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reversal of EMT, inhibition of migration and invasion. 
Meanwhile with PNT2 cells, IGFBP-2 silencing resulted 
in partial repression of EMT as demonstrated by up-
regulation in the epithelial marker E-cadherin but no 
observed changes in mesenchymal markers. Surprisingly, 
the migratory and invasive potential of PNT2 cells were 
increased with a reduction in IGFBP-2 levels.
These data suggest that FOXA1 and IGFBP-2 each 
contribute to the process of glucose-induced EMT and 
that the level of binding of FOXA1 with the IGFBP gene 
plays a role. In summary, IGF-I and hyperglycaemia-
induced FOXA1/IGFBP-2 play important roles in 
promoting prostate cancer cell progression. These data 
may underpin why men with prostate cancer, who present 
with hyperglycaemia, have a worse prognosis and may 
lead to new potential therapeutic strategies.
MATERIALS AND METHODS
Human, recombinant IGF-I was purchased from 
Gropep (Adelaide, Australia) and an IGF-IR inhibitor, 
AG1024, was obtained from Sigma-Aldrich, Dorset, UK.
Cell culture
A normal epithelial prostate cell line, PNT2 was 
purchased from ECACC (London, UK) and DU145 
and LNCaP prostate cancer cells were purchased from 
ATCC (Teddington, Middlesex, UK). All cell lines were 
cultured as described previously [18]. These cells have 
been authenticated by short tandem repeat (STR) analysis 
and had been confirmed as mycoplasma-negative in our 
routine quality control.
Cell proliferation assay
Trypan Blue dye exclusion assay was performed to 
assess cell proliferation as described previously [40].
Transwell migration and invasion assay
These were performed as described previously 
[41]. To assess the migratory potential, cells were seeded 
into the upper chamber of a cell permeable membrane of 
8 mm pore trans-well inserts and to create an invasion 
assay, the cell permeable membrane was coated with 
collagen (1%), to mimic the extracellular matrix that cells 
encounter during the invasion process. 1% solution v/v of 
collagen type I was prepared by diluting stock solution 
with PBS. 200ml of working solution was added to the 
upper chamber of the trans-well inserts. The inserts were 
dried overnight prior to seeding the cells.
siRNA and transfections
IGFBP-2 siRNA was used as described previously 
[18]. ON-TARGETplus SMARTpool FOXA1 siRNAs 
were bought from Dharmacon Thermo Scientific 
(Lafayette, CO, USA). The transfection kit was 
purchased from Synvolux Therapeutics (Leiden, The 
Netherlands) and transfection was conducted following 
the manufacturer’s instructions.
Western immunoblotting
Western blot analysis was performed as described 
previously [40]. Briefly, 30 μg of protein were run on 
10% SDS-PAGE, transferred to nitrocellulose membrane 
(BioRad, Hertfordshire, UK) and immunoblotted with the 
following antibodies: E-cadherin (1:1000, Cell Signaling 
Hertfordshire, UK), vimentin (1:500, BD Biosciences 
Oxford, UK), fibronectin (1:500, BD Biosciences Oxford, 
UK), FOXA1(1:100, Abcam), IGFBP-2(1:1000, Santa 
Cruz Heidelberg, Germany), MAPK (Erk1/2)(1:1000, 
Cell Signaling Hertfordshire, UK), AKT (1:1000, Cell 
Signaling Hertfordshire, UK), p-AKT (S473)(1:1000, Cell 
Signaling Hertfordshire, UK), p-IGF1-R/IR (1:1000, Cell 
Signalling), p- MAPK (Erk1/2; Thr202/Tyr204)(1:1000, 
Cell Signaling Hertfordshire, UK), GAPDH (1:5000, 
Merck Millipore Hertfordshire, UK) and tubulin (1:5000, 
Merck Millipore Hertfordshire, UK), following the 
manufacturer’s instructions. After incubation with specific 
secondary antibodies conjugated to peroxidase (Sigma-
Aldrich, Dorset, UK.), proteins were visualised by Clarity 
ECL substrate (BioRad, Hertfordshire, UK) using BioRad 
Chemidoc XRS + system and analysed using Image lab 
software (BioRad, Hertfordshire, UK).
Chromatin immunoprecipitation (ChIP) assay
A ChIP assay was performed in order to assess the 
interaction between FOXA1 and the Igfbp2 promoter. The 
Pierce Agarose ChIP Kit (Thermo Scientific) was used 
and was carried out as per the manufacturer’s instructions. 
Briefly, cells were cultured under conditions of high 
glucose and 2 × 106 cells per ChIP reaction were cross-
linked with formaldehyde and digested by Micrococcal 
Nuclease Digestion. DNA fragments bound to FOXA1 
were immunoprecipitated using a ChIP-grade antibody 
(5µg per reaction, Thermo Fisher). DNA was recovered 
and cleaned then qPCR performed as we have described 
previously [18] to determine the quantitity of IGFBP-2-
bound to FOXA1.
Tissue samples
We obtained two separate cohorts of human prostate 
tissue samples, the clinical and pathological data of 
which are summarised in Table 1. The first cohort of 47 
samples was collected from patients with prostate cancer 
that underwent prostatectomy from years 2008-2015 
The second cohort of 95 samples was collected for the 
Prostate: Evidence for Exercise and Nutrition (PrEvENT). 
Trial samples for each study were collected at Southmead 
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Hospital, Bristol, with full ethical approval (15/WM/0449 
and 14/SW/0056 respectively). For these studies men 
were consented to allow prostate tissue samples to be 
obtained from the prostate that was removed at the time of 
surgery [42]. All samples collected, were used and stored 
in accordance with the Human Tissue Act 2004 and the 
study was performed in accordance with the Declaration 
of Helsinki. Prostate tissue sections that were used were 
formalin-fixed and the tissue was surplus to diagnostic 
requirements. It was paraffin embedded before being cut to 
4µm thickness and collected on adhesive slides. Patient’s 
clinical and pathological data including age at surgery, 
pre-surgery PSA level, Gleason and histological grade 
and lymph node invasion were extracted and analysed 
anonymously from medical records for the purpose of this 
study.
Immunohistochemistry
All reagents were purchased from Ventana Medical 
Systems unless stated otherwise. The tissues were 
stained using a fully automated Ventana BenchMark 
Ultra Immunostainer system (Ventana Medical Systems) 
following the manufacturer’s protocol. Briefly, the cut 
paraffin sections were dried at 60° C for 1 hour on a 
microslide prior to immunostaining. Each individual slide 
was installed onto the slide carousel and the program 
was run to completion. The ventana staining procedure 
includes deparaffinisation and pretreatment with cell 
conditioner. Upon cell conditioning, a primary antibody 
against IGFBP-2 or FOXA1 was manually added onto 
each slide and incubated for 2 hours. The slides were then 
counterstained with Hematoxylin for 8 minutes and with 
bluing reagent for another 4 minutes. The slides were 
then dehydrated and mounted in distyrene plasticizer 
and xylenemountant (DPX)(SIGMA). An Allred scoring 
system was used to assess IGFBP-2 and FOXA1 staining 
as we described previously [43].
Statistical analyses
Data are represented as the mean ± SEM from 
three independent experiments each repeated in triplicate 
unless otherwise stated. Statistical analysis was performed 
using IBM SPSS statistics 23(IBM Corporation, version 
23.0.0.2). Independent samples t-test was used to 
compare means of two groups. One-way Analysis of 
variance (ANOVA) was used for multiple comparisons 
followed by least significant difference (LSD) post hoc 
test. A significant difference was considered present at 
p < 0.05. CHIP experiment data were analysed using a 
fold enrichment method (alternatively called “signal over 
background”) where dCt values (delta cycle threshold) 
were calculated by subtracting Ct for negative control (no 
antibody) from Ct values for individual samples. Next 
a fold enrichment method was calculated using formula 
2^-(dCt) for each individual sample. The ChIP assay was 
performed three times and statistical differences between 
the means of these fold changes were calculated using 
one-way Anova with Least Significant Difference post-
hoc test at significance level equal to 0.05. Differences 
in FOXA1 and IGFBP-2 staining between benign and 
prostate cancer tissue were calculated using Mann-
Whitney rank –sum test. The Pearson χ2 chi square test or 
Fisher’s exact test was used to test the differences between 
FOXA1/ IGFBP-2 abundance and clinicopathological 
parameters. The Spearman’s rank correlation coefficient 
was used to assess the correlation between IGFBP-2 and 
FOXA1 levels.
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